<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">667947</article-id>
<article-id pub-id-type="doi">10.3389/fmolb.2021.667947</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Bioinformatic Analyses of Canonical Pathways of TSPOAP1 and its Roles in Human Diseases</article-title>
<alt-title alt-title-type="left-running-head">Suthar et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Canonical Pathways and Roles of TSPOAP1</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Suthar</surname>
<given-names>Sharad Kumar</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1117688/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alam</surname>
<given-names>Mohammad Maqusood</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1336095/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jihye</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1224193/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Monga</surname>
<given-names>Jitender</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1329069/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Joseph</surname>
<given-names>Alex</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/382571/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lee</surname>
<given-names>Sang-Yoon</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/645017/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Neuroscience Research Institute, Gachon University, <addr-line>Incheon</addr-line>, <country>South Korea</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Manipal College of Pharmaceutical Sciences, Manipal University, <addr-line>Manipal</addr-line>, <country>India</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Medicinal Chemistry, Institut Pasteur Korea, <addr-line>Seongnam</addr-line>, <country>South Korea</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Department of Urology, Postgraduate Institute of Medical Education and Research, <addr-line>Chandigarh</addr-line>, <country>India</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Department of Neuroscience, College of Medicine, Gachon University, <addr-line>Incheon</addr-line>, <country>South Korea</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/95523/overview">Barbara Bardoni</ext-link>, UMR7275 Institut de pharmacologie mol&#xe9;culaire et cellulaire (IPMC), France</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1268709/overview">Leo Veenman</ext-link>, Consorzio per Valutazioni Biologiche e Farmacologiche, Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/182068/overview">Enzo Lalli</ext-link>, UMR7275 Institut de pharmacologie mol&#xe9;culaire et cellulaire (IPMC), France</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Sang-Yoon Lee, <email>rchemist@gachon.ac.kr</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Protein and RNA Networks, a section of the journal Frontiers in Molecular Biosciences</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>8</volume>
<elocation-id>667947</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>02</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>05</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Suthar, Alam, Lee, Monga, Joseph and Lee.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Suthar, Alam, Lee, Monga, Joseph and Lee</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>TSPO-associated protein 1 (TSPOAP1) is a cytoplasmic protein and is closely associated with its mitochondrial transmembrane protein partner translocator protein (TSPO). To decipher the canonical signalling pathways of TSPOAP1, its role in human diseases and disorders, and relationship with TSPO; expression analyses of TSPOAP1- and TSPO-associated human genes were performed by Qiagen Ingenuity Pathway Analysis (IPA). In the expression analysis, necroptosis and sirtuin signalling pathways, mitochondrial dysfunction, and inflammasome were the top canonical pathways for both TSPOAP1 and TSPO, confirming the close relationship between these two proteins. A distribution analysis of common proteins in all the canonical pathways predicted for TSPOAP1 revealed that tumor necrosis factor receptor 1 (TNFR1), vascular cell adhesion molecule 1 (VCAM1), cyclic AMP response element-binding protein 1 (CREB1), T-cell receptor (TCR), nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing 3 (NLRP3), DNA-dependent protein kinase (DNA-PK or PRKDC), and mitochondrial permeability transition pore (mPTP) were the major interaction partners of TSPOAP1, highlighting the role of TSPOAP1 in inflammation, particularly neuroinflammation. An analysis of the overlap between TSPO and TSPOAP1&#x20;<italic>Homo sapiens</italic> genes and top-ranked canonical pathways indicated that TSPO and TSPOAP1 interact <italic>via</italic> voltage-dependent anion-selective channels (VDAC1/2/3). A heat map analysis indicated that TSPOAP1 has critical roles in inflammatory, neuroinflammatory, psychiatric, and metabolic diseases and disorders, and cancer. Taken together, this information improves our understanding of the mechanism of action and biological functions of TSPOAP1 as well as its relationship with TSPO; furthermore, these results could provide new directions for in-depth functional studies of TSPOAP1 aimed at unmasking its detailed functions.</p>
</abstract>
<kwd-group>
<kwd>TSPO</kwd>
<kwd>TSPOAP1</kwd>
<kwd>IPA</kwd>
<kwd>canonical pathway analysis</kwd>
<kwd>mitochondrial dysfunction</kwd>
<kwd>neuroinflammation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>TSPO is an 18-kDa transmembrane protein of 169 residues predominantly localized in the outer mitochondrial membrane (<xref ref-type="bibr" rid="B10">Delavoie et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B24">Iacobazzi et&#x20;al., 2017</xref>) (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). It was first discovered in 1977 in a diazepam-binding site in the kidney and named peripheral-type benzodiazepine receptor (PBR) (<xref ref-type="bibr" rid="B6">Braestrup and Squires 1977</xref>). TSPO is a highly conserved ubiquitous protein with high abundance in steroid-producing tissues, including the glial cells, adrenal glands, testis, and ovary (<xref ref-type="bibr" rid="B14">Gali&#xe8;gue et&#x20;al., 1999</xref>). The characteristic function of TSPO is cholesterol transport from the outer mitochondrial membrane to the inner membrane (<xref ref-type="bibr" rid="B43">Papadopoulos et&#x20;al., 2007</xref>). Other functions of TSPO are the formation of mitochondrial permeability transition pore (mPTP) in conjunction with VDAC in the outer mitochondrial membrane, adenine nucleotide transporter (ANT) in the inner mitochondrial membrane, and cyclophilin D (<xref ref-type="bibr" rid="B54">Veenman et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B11">Dimitrova-Shumkovska et&#x20;al., 2020</xref>). However, the role of TSPO, VDAC, and ANT in mPTP formation remains debated (<xref ref-type="bibr" rid="B31">Kokoszka et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B3">Baines et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B46">&#x160;ileikyt&#x117; et&#x20;al., 2014</xref>). On activation, TSPO generates reactive oxygen species that opens mPTP and release cytochrome C into the cytosol through the Bax-Bak channel, which leads to cell death (<xref ref-type="bibr" rid="B16">Garrido et&#x20;al., 2006</xref>; <xref ref-type="bibr" rid="B53">Veenman et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B54">Veenman et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B58">Zeineh et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B11">Dimitrova-Shumkovska et&#x20;al., 2020</xref>). The increased level of TSPO has been observed in neurodegenerative diseases and disorders (<xref ref-type="bibr" rid="B45">Rupprecht et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B1">Alam et&#x20;al., 2017</xref>), brain injury (<xref ref-type="bibr" rid="B42">Papadopoulos and Lecanu 2009</xref>), and cancer (<xref ref-type="bibr" rid="B9">Decaudin et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B37">Li et&#x20;al., 2007</xref>), while the dysregulation of TSPO has been detected in obesity (<xref ref-type="bibr" rid="B29">Kim et&#x20;al., 2020</xref>) and diabetes (<xref ref-type="bibr" rid="B18">Giatti et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B25">Ilkan and Akar 2018</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Three-dimensional crystal structures of TSPO and TSPOAP1. Helix&#x2013;Red, Sheet&#x2013;Yellow, and Loop&#x2013;Green.</p>
</caption>
<graphic xlink:href="fmolb-08-667947-g001.tif"/>
</fig>
<p>TSPOAP1, also known as PBR-associated protein 1 (PRAX-1), is a cytoplasmic protein of 1857 residues (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>), was discovered in 1999 (<xref ref-type="bibr" rid="B14">Gali&#xe8;gue et&#x20;al., 1999</xref>). As is evident from the name, TSPOAP1 specifically interacts with TSPO (<xref ref-type="bibr" rid="B14">Gali&#xe8;gue et&#x20;al., 1999</xref>), and their functions and clinical applications overlap with each other. The modulation of TSPOAP1 activity has been implicated in neurodegenerative diseases and disorders (<xref ref-type="bibr" rid="B5">Blasi 2000</xref>; <xref ref-type="bibr" rid="B28">Jun et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B55">Witoelar et&#x20;al., 2018</xref>), cancer (<xref ref-type="bibr" rid="B14">Gali&#xe8;gue et&#x20;al., 1999</xref>), and obesity (<xref ref-type="bibr" rid="B57">Yim et&#x20;al., 2020</xref>). The biological functions of TSPOAP1 are thought to be similar to those of its counterpart TSPO. Although it has been two decades since its discovery, very little is known about the functions and interaction partners of TSPOAP1 and its interplay with TSPO. The lack of canonical signalling information for TSPOAP1 limits molecular biology studies at various levels and the development of ligands as biological tools and therapeutics.</p>
<p>In this study, we deciphered the canonical signalling pathways of TSPOAP1, its protein interaction partners, and its roles in human diseases and disorders. We also analyzed the relationship between TSPOAP1 and TSPO and their common and unique interacting proteins or genes, providing insight into their overlapping and distinct biological functions. As a whole, this work is useful for researchers focused on the detailed molecular mechanisms and biological functions of TSPOAP1 and provides a basis for laboratory experiments aimed at unravelling the complex relationship between TSPOAP1 and&#x20;TSPO.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>TSPOAP1 and TSPO Datasets</title>
<p>TSPOAP1 and TSPO genes available up to September 7, 2020 were searched in the National Center for Biotechnology (NCBI) database (<xref ref-type="bibr" rid="B40">NCBI, 2020</xref>) with the search terms &#x201c;TSPO associated protein one&#x201d; and &#x201c;TSPO,&#x201d; respectively, (<xref ref-type="sec" rid="s10">Supplementary Tables S1, S2</xref>). The results were limited to the taxon <italic>Homo sapiens</italic> and were downloaded as text files for subsequent analyses.</p>
</sec>
<sec id="s2-2">
<title>Building and Analysis of TSPOAP1 and TSPO Interaction Networks</title>
<p>The core analyses (interaction networks or interaction pathways) of TSPOAP1 and TSPO were built and analyzed using Ingenuity Pathway Analysis (IPA), Qiagen (<xref ref-type="bibr" rid="B26">IPA, 2020a</xref>). The gene file of the respective TSPOAP1 or TSPO protein obtained from the NCBI database was uploaded to the IPA server for the &#x201c;core analysis&#x201d; in the flexible format. The gene identification (GI) number was defined and the &#x201c;expression analysis&#x201d; as a type was chosen for the new core analysis. The population of genes considered for <italic>p</italic>-value calculations was restricted to the Ingenuity Knowledge Base only (defining the reference set), while opting for both direct and indirect relationships among genes affecting interaction networks and upstream regulators. For pre-analysis filtering of networks, for interaction networks; genes, including endogenous chemicals, 35 molecules per network and 25 networks per analysis were selected. For casual networks that relate to master regulators for relationships to diseases, functions, genes, or chemicals selection, were also ticked along with the option &#x201c;score using casual paths only.&#x201d; The node types (molecule types filter) in the IPA represent different canonical pathways, proteins, genes, endogenous and exogenous chemicals, diseases, drugs, and their biological functions and effects, which allows us to build pathways based upon the types we select. For core analyses, all node types available on the IPA server were selected. The data source in IPA allows us to select the particular data sets for our analysis. For the TSPOAP1 and TSPO core analyses, all data sources available on the IPA server were selected. Among other parameters for pathway building, only experimentally observed confidence was selected (filter for the selection of microRNAs involved in interaction networks) and species selection was restricted to humans only (filter for the selection of molecules and relationship to specific species). All types of tissues and cell lines as well as all kinds of mutations, such as functional, inherited, translation, zygotic, wild-type, and other unclassified mutations, were chosen to build the interaction networks (<xref ref-type="bibr" rid="B27">IPA, 2020b</xref>). The results were ranked based on Fisher&#x2019;s exact test, where smaller <italic>p</italic>-values indicate a lower likelihood of a random association between the data set and predictions. GraphPad Prism 6 was used at various stages of the analyses to plot the results.</p>
</sec>
<sec id="s2-3">
<title>Preparation of 3-Dimensional Crystal Structures of TSPO and TSPOAP1</title>
<p>The 3-D crystal structure of TSPO was downloaded from RCSB Protein Data Bank (PDB ID: 2MGY). The 3-D crystal structure of TSPOAP1 was prepared by homology modeling using the Swiss-Model server (<xref ref-type="bibr" rid="B48">Swiss-Model 2020</xref>). For this, the FASTA sequence of TSPOAP1 (UniProtKB ID: O95153, <xref ref-type="bibr" rid="B50">UniProt, 2020</xref>) isoform 1 (identifier: O95153-1) was submitted to the Swiss-Model server. The obtained models were ranked based on various parameters and the model with the highest sequence similarity was used for the presentation of the 3-D crystal structure of TSPOAP1. PyMOL was used for the visualization of the 3-D crystal structures of TSPO and TSPOAP1.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Identification of Canonical Pathways Associated With TSPOAP1 and TSPO</title>
<p>TSPOAP1 is closely associated with TSPO (<xref ref-type="bibr" rid="B14">Gali&#xe8;gue et&#x20;al., 1999</xref>). Despite extensive studies of the mechanism of action and biological functions of TSPO (<xref ref-type="bibr" rid="B34">Lee et&#x20;al., 2020</xref>), very little is known about the roles and functions of TSPOAP1 in human diseases and disorders. Accordingly, to characterize the functions of TSPOAP1 and its interactions with TSPO, we performed canonical pathway analyses, including expression analyses of signalling molecules related to both TSPOAP1 and TSPO using IPA. The canonical pathway analysis of <italic>Homo sapiens</italic> genes associated with TSPOAP1 (<xref ref-type="sec" rid="s10">Supplementary Table S1</xref>) and TSPO (<xref ref-type="sec" rid="s10">Supplementary Table S2</xref>) identified the necroptosis, sirtuin signalling, mitochondrial dysfunction, and inflammasome pathways as the major signalling pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref> and <xref ref-type="sec" rid="s10">Supplementary Figures S1&#x2013;S8</xref>). All the canonical pathways predicted by IPA for TSPOAP1 and TSPO are summarized in <xref ref-type="table" rid="T1">Table&#x20;1</xref> and <xref ref-type="sec" rid="s10">Supplementary Table S4</xref>, respectively, and in <xref ref-type="sec" rid="s10">Supplementary Figure&#x20;S1</xref>.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> Top-ranked common canonical pathways of TSPOAP1 and TSPO. <bold>(B)</bold> Interaction partners of TSPOAP1 in the canonical pathways. <bold>(C</bold>) Interaction partners of TSPO in the canonical pathways. <bold>(D)</bold> Overlapping of top-ranked canonical pathways of TSPOAP1, highlighting the common enzymes, proteins, and genes in these signalling pathways. <bold>(E)</bold> Top-five human diseases and disorders and functions associated with TSPOAP1. Symbols in <xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>: TSPO and TNFRSF11B; transmembrane receptor, VDAC 1/2/3; ion channel, NLRP3; complex/group/other, ATP5PO, ATP5F1A, and PANX1; transporter, ATP5MG; enzyme, PRKDC; kinase.</p>
</caption>
<graphic xlink:href="fmolb-08-667947-g002.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Canonical pathways of TSPOAP1 predicted by Ingenuity Pathway Analysis, highlighting the interacting protein or gene partners in the signalling pathways.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Rank</th>
<th align="center">Canonical pathway</th>
<th align="center">-log(<italic>p</italic>-value)</th>
<th align="center">
<italic>p</italic>-value</th>
<th align="center">Interacting pathway proteins/genes</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="3" align="left">1</td>
<td rowspan="3" align="left">Necroptosis signalling pathway</td>
<td rowspan="3" align="char" char=".">6.728</td>
<td rowspan="3" align="left">1.87E<sup>&#x2212;07</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- NLRP3 inflammasome or Caspase-1 inflammasome (Nalp3, Asc, Csp1)</td>
</tr>
<tr>
<td align="left">- PPIF and Mpt pore (mPTP)</td>
</tr>
<tr>
<td rowspan="3" align="left">2</td>
<td rowspan="3" align="left">Sirtuin signalling pathway</td>
<td rowspan="3" align="char" char=".">5.171</td>
<td rowspan="3" align="left">6.74E<sup>&#x2212;06</sup>
</td>
<td align="left">- Mpt pore (mPTP)</td>
</tr>
<tr>
<td align="left">- OXPHOS &#x2013; Mitochondrial complex 1 (NDUFA9, SDHA, ATP5<italic>&#x3b2;</italic>) (MC 1)</td>
</tr>
<tr>
<td align="left">- DNA-PK (PRKDC)</td>
</tr>
<tr>
<td rowspan="2" align="left">3</td>
<td rowspan="2" align="left">Mitochondrial dysfunction</td>
<td rowspan="2" align="char" char=".">5.115</td>
<td rowspan="2" align="left">7.67E<sup>&#x2212;06</sup>
</td>
<td align="left">- VDAC</td>
</tr>
<tr>
<td align="left">- Mitochondrial complex V or mitochondrial ATP synthase ((MC V)</td>
</tr>
<tr>
<td rowspan="2" align="left">4</td>
<td rowspan="2" align="left">Inflammasome pathway</td>
<td rowspan="2" align="char" char=".">3.295</td>
<td rowspan="2" align="left">5.07E<sup>&#x2212;04</sup>
</td>
<td align="left">- NLRP3 inflammasome or Caspase-1 inflammasome (Nalp3, Asc, Csp1)</td>
</tr>
<tr>
<td align="left">- PANX1</td>
</tr>
<tr>
<td rowspan="3" align="left">5</td>
<td rowspan="3" align="left">Granulocyte adhesion and diapedesis</td>
<td rowspan="3" align="char" char=".">2.582</td>
<td rowspan="3" align="left">2.62E<sup>&#x2212;03</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td align="left">- L-Selectin</td>
</tr>
<tr>
<td rowspan="3" align="left">6</td>
<td rowspan="3" align="left">Dendritic cell maturation</td>
<td rowspan="3" align="char" char=".">2.523</td>
<td rowspan="3" align="left">3.00E<sup>&#x2212;03</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- TCR</td>
</tr>
<tr>
<td align="left">- CREB1</td>
</tr>
<tr>
<td rowspan="2" align="left">7</td>
<td rowspan="2" align="left">T Helper cell differentiation</td>
<td rowspan="2" align="char" char=".">2.225</td>
<td rowspan="2" align="left">5.95E<sup>&#x2212;03</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- TCR</td>
</tr>
<tr>
<td rowspan="2" align="left">8</td>
<td rowspan="2" align="left">SAPK/JNK signalling</td>
<td rowspan="2" align="char" char=".">1.907</td>
<td rowspan="2" align="left">1.24E<sup>&#x2212;02</sup>
</td>
<td align="left">- TCR</td>
</tr>
<tr>
<td align="left">- JIP 1/2/3</td>
</tr>
<tr>
<td rowspan="3" align="left">9</td>
<td rowspan="3" align="left">Neuroinflammation signalling pathway</td>
<td rowspan="3" align="char" char=".">1.907</td>
<td rowspan="3" align="left">1.24E<sup>&#x2212;02</sup>
</td>
<td align="left">- NLRP3 inflammasome or Caspase-1 inflammasome (Nalp3, Asc, Csp1)</td>
</tr>
<tr>
<td align="left">- CREB1</td>
</tr>
<tr>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td rowspan="4" align="left">10</td>
<td rowspan="4" align="center">Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis</td>
<td rowspan="4" align="char" char=".">1.886</td>
<td rowspan="4" align="center">1.36E<sup>&#x2212;02</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- TNFR SF11B or OPG</td>
</tr>
<tr>
<td align="left">- CREB1</td>
</tr>
<tr>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td align="left">11</td>
<td align="left">Oxidative phosphorylation</td>
<td align="char" char=".">1.883</td>
<td align="left">1.31E<sup>&#x2212;02</sup>
</td>
<td align="left">- Mitochondrial complex V or mitochondrial ATP synthase (MC V)</td>
</tr>
<tr>
<td align="left">12</td>
<td align="left">Salvage pathways of pyrimidine deoxyribonucleotides</td>
<td align="char" char=".">1.876</td>
<td align="left">1.33E<sup>&#x2212;02</sup>
</td>
<td align="left">- Thymidine kinase 1 (TK1)</td>
</tr>
<tr>
<td rowspan="2" align="left">13</td>
<td rowspan="2" align="left">Type 1 Diabetes Mellitus signalling</td>
<td rowspan="2" align="char" char=".">1.86</td>
<td rowspan="2" align="left">1.38E<sup>&#x2212;02</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- TCR</td>
</tr>
<tr>
<td rowspan="3" align="left">14</td>
<td rowspan="3" align="left">Estrogen receptor signalling</td>
<td rowspan="3" align="char" char=".">1.788</td>
<td rowspan="3" align="left">1.63E<sup>&#x2212;02</sup>
</td>
<td align="left">- CREB1</td>
</tr>
<tr>
<td align="left">- TRAP/Mediator complex</td>
</tr>
<tr>
<td align="left">- OXPHOS</td>
</tr>
<tr>
<td rowspan="2" align="left">15</td>
<td rowspan="2" align="left">White adipose tissue browning pathway</td>
<td rowspan="2" align="char" char=".">1.712</td>
<td rowspan="2" align="left">1.94E<sup>&#x2212;02</sup>
</td>
<td align="left">- E2F-DP1</td>
</tr>
<tr>
<td align="left">- CREB1</td>
</tr>
<tr>
<td rowspan="3" align="left">16</td>
<td rowspan="3" align="left">Hepatic fibrosis signalling pathway</td>
<td rowspan="3" align="char" char=".">1.654</td>
<td rowspan="3" align="left">2.22E<sup>&#x2212;02</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- CREB</td>
</tr>
<tr>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">DNA double-strand break repair by non-homologous end joining</td>
<td align="char" char=".">1.635</td>
<td align="left">2.32E<sup>&#x2212;02</sup>
</td>
<td align="left">- DNA-PK (PRKDC)</td>
</tr>
<tr>
<td rowspan="2" align="left">18</td>
<td rowspan="2" align="left">Role of pattern recognition receptors in recognition of bacteria and viruses</td>
<td rowspan="2" align="char" char=".">1.616</td>
<td rowspan="2" align="left">2.42E<sup>&#x2212;02</sup>
</td>
<td align="left">- NLRP3</td>
</tr>
<tr>
<td align="left">- CREB1</td>
</tr>
<tr>
<td align="left">19</td>
<td align="left">Granzyme B signalling</td>
<td align="char" char=".">1.577</td>
<td align="left">2.65E<sup>&#x2212;02</sup>
</td>
<td align="left">- DNA-PK (PRKDC)</td>
</tr>
<tr>
<td rowspan="2" align="left">20</td>
<td rowspan="2" align="left">HMGB1</td>
<td rowspan="2" align="char" char=".">1.547</td>
<td rowspan="2" align="left">2.84E<sup>&#x2212;02</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td align="left">21</td>
<td align="left">CDP-diacylglycerol biosynthesis I</td>
<td align="char" char=".">1.481</td>
<td align="left">3.3E<sup>&#x2212;02</sup>
</td>
<td align="left">- 1-Acylglycerol-3-phosphate-O-acyltransferase&#xa0;(AGPAT1)</td>
</tr>
<tr>
<td rowspan="2" align="left">22</td>
<td rowspan="2" align="left">Agranulocyte adhesion and diapedesis</td>
<td rowspan="2" align="char" char=".">1.456</td>
<td rowspan="2" align="left">3.5E<sup>&#x2212;02</sup>
</td>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td align="left">- L-Selectin</td>
</tr>
<tr>
<td rowspan="2" align="left">23</td>
<td rowspan="2" align="left">NF-kB signalling</td>
<td rowspan="2" align="char" char=".">1.456</td>
<td rowspan="2" align="left">3.5E<sup>&#x2212;02</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- TCR</td>
</tr>
<tr>
<td rowspan="2" align="left">24</td>
<td rowspan="2" align="left">Acute phase response signalling</td>
<td rowspan="2" align="char" char=".">1.447</td>
<td rowspan="2" align="left">3.57E<sup>&#x2212;02</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- RBP</td>
</tr>
<tr>
<td align="left">25</td>
<td align="left">Glutathione redox reactions I</td>
<td align="char" char=".">1.441</td>
<td align="left">3.62E<sup>&#x2212;02</sup>
</td>
<td align="left">- Glutathione peroxidase 1 (GPX1)</td>
</tr>
<tr>
<td align="left">26</td>
<td align="left">Phosphatidylglycerol biosynthesis II (non-plastidic)</td>
<td align="char" char=".">1.441</td>
<td align="left">3.62E<sup>&#x2212;02</sup>
</td>
<td align="left">- 1-Acylglycerol-3-phosphate-O-acyltransferase&#xa0;(AGPAT1)</td>
</tr>
<tr>
<td rowspan="2" align="left">27</td>
<td rowspan="2" align="left">Hepatic fibrosis/Hepatic stellate cell activation</td>
<td rowspan="2" align="char" char=".">1.429</td>
<td rowspan="2" align="left">3.72E<sup>&#x2212;02</sup>
</td>
<td align="left">- TNFR1</td>
</tr>
<tr>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td align="left">28</td>
<td align="left">Lipid antigen presentation by CD1</td>
<td align="char" char=".">1.405</td>
<td align="left">3.94E<sup>&#x2212;02</sup>
</td>
<td align="left">- TCR</td>
</tr>
<tr>
<td rowspan="2" align="left">29</td>
<td rowspan="2" align="left">Natural killer cell signalling</td>
<td rowspan="2" align="char" char=".">1.391</td>
<td rowspan="2" align="left">4.06E<sup>&#x2212;02</sup>
</td>
<td align="left">- FCER1G</td>
</tr>
<tr>
<td align="left">- PVR</td>
</tr>
<tr>
<td rowspan="2" align="left">30</td>
<td rowspan="2" align="left">Leukocyte extravasation signalling</td>
<td rowspan="2" align="char" char=".">1.384</td>
<td rowspan="2" align="left">4.13E<sup>&#x2212;02</sup>
</td>
<td align="left">- VCAM1</td>
</tr>
<tr>
<td align="left">- ICAM3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<bold>TNFR1</bold>, Tumor necrosis factor receptor 1; <bold>NLRP3</bold>, Nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing 3; <bold>ASC</bold>, Apoptosis-associated speck-like protein containing a CARD; <bold>Csp1</bold>, Caspase-1; <bold>PPIF</bold>, Peptidylprolyl isomerase F; <bold>Mpt pore (mPTP)</bold>, Mitochondrial permeability transition pore; <bold>NDUFA9</bold>, NADH-ubiquinone oxidoreductase subunit A9; <bold>SDHA</bold>, Succinate dehydrogenase complex flavoprotein subunit 9; <bold>ATP5<italic>&#x3b2;</italic>
</bold>, ATP synthase F1 subunit <italic>&#x3b2;</italic>; <bold>DNA-PK (PRKDC)</bold>, DNA-dependent protein kinase; <bold>PANX1</bold>, Pannexin 1; <bold>TCR</bold>, T-cell receptor; <bold>CREB</bold>, Cyclic AMP response element binding protein 1; <bold>JIP 1/2/3</bold>, JNK-interacting protein 1/2/3; <bold>VCAM1</bold>, Vascular cell adhesion molecule 1; <bold>OPG</bold>, Osteoprotegerin; <bold>TRAP/Mediator complex</bold>, Thyroid hormone receptor-associated protein (TRAP)/Mediator coactivator complex; <bold>OXPHOS</bold>, Oxidative phosphorylation; <bold>E2F</bold>, E2 factor family of transcription factors; <bold>DP1</bold>, transcription factor dimerization partner; <bold>AGPAT1</bold>, 1-Acylglycerol-3-phosphate-O-acyltransferase; <bold>RBP</bold>, Retinol-binding protein; <bold>FCER1G</bold>, Fc fragment of IgE receptor Ig; <bold>PVR</bold>, PVR cell adhesion molecule; <bold>ICAM3</bold>, Intercellular adhesion molecule 3</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3-2">
<title>Analysis of Protein Interaction Networks of TSPOAP1 and TSPO</title>
<p>After predicting canonical pathways, we analyzed the interacting proteins of TSPOAP1 and TSPO in those pathways. In all the predicted canonical pathways, TNFR1, VCAM1, CREB1, NLRP3, and DNA-PK were the major and common interacting partners of both TSPOAP1 and TSPO (<xref ref-type="fig" rid="F2">Figures 2B,C</xref>). Other common interacting partners between TSPOAP1 and TSPO were mitochondrial ATP synthase (MC V), L-selectin, AGPAT1, and VDAC. These common interacting partners suggest overlapping functions and roles of TSPOAP1 and TSPO. Since the most prominent signalling pathways were shared by both TSPOAP1 and TSPO (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>), we focused on the differences in proteins that interact with TSPOAP1 and TSPO in the canonical pathways. Upon distribution analysis of interacting proteins in the pathways, we observed that TCR and m-PTP were significantly populated in TSPOAP1 signalling, whereas MAP3K10 and FCERIG more frequently appeared in TSPO signalling. Furthermore, VDAC1/2/3, responsible for transport between the mitochondria and cytosol (<xref ref-type="bibr" rid="B21">Hiller et&#x20;al., 2010</xref>), were also more frequent in the TSPO pathways.</p>
</sec>
<sec id="s3-3">
<title>Identification of Cross-Talk Mediator Between TSPOAP1 and TSPO</title>
<p>To establish the relationship between TSPOAP1 and TSPO, we evaluated the overlap between their prominent signalling pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref> and <xref ref-type="sec" rid="s10">Supplementary Figures S4&#x2013;S8</xref>) and <italic>Homo sapiens</italic> genes associated with TSPOAP1 and TSPO (<xref ref-type="sec" rid="s10">Supplementary Tables S1&#x2013;S3</xref>). Overlapping of signalling cascades and genes revealed VDAC1/2/3 as the key mediators of the relationship between TSPOAP1 and TSPO (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>).</p>
</sec>
<sec id="s3-4">
<title>Prediction of Pathological Conditions and Functions Associated With TSPOAP1 and TSPO</title>
<p>A heat map analysis by IPA was used to predict the major diseases and functions associated with TSPOAP1 and TSPO. It predicted quantity of phosphatidylglycerol, Alzheimer&#x2019;s disease, progressive neurological disorder, adhesion of acute myeloid leukemia blast cells, and adhesion of human coronary artery endothelial cells (HCAEC) (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref> and <xref ref-type="sec" rid="s10">Supplementary Figures S9, S10</xref>) as the major diseases and functions associated with TSPOAP1. The major diseases and disorders predicted for TSPO were inflammatory, neuroinflammatory and psychiatric diseases and disorders, cancer, and metabolic syndrome (<xref ref-type="fig" rid="F2">Supplementary Figures S11,&#x20;S12</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<sec id="s4-1">
<title>IPA Predicts Canonical Pathways of TSPOAP1 and TSPO</title>
<p>Our IPA-based canonical pathway analysis identified several signalling pathways associated with TSPOAP1 and TSPO. Based on their significance potential, necroptosis, sirtuin signalling, mitochondrial dysfunction, and inflammasome pathways were identified as the major signalling pathways of TSPOAP1 and TSPO. Necroptosis is a type of cell death, which occurs with a regulated mechanism like apoptosis (<xref ref-type="bibr" rid="B15">Galluzzi and Kroemer 2008</xref>). Neurodegenerative diseases are characterized by chronic neuroinflammation and neuronal death (<xref ref-type="bibr" rid="B20">Heckmann et&#x20;al., 2019</xref>). Inhibition of necroptosis mediators leads to reduced tissue inflammation (<xref ref-type="bibr" rid="B15">Galluzzi and Kroemer 2008</xref>). The mechanisms of neuronal degeneration are not well understood; however, an extensive interplay between various pathways has been indicated (<xref ref-type="bibr" rid="B20">Heckmann et&#x20;al., 2019</xref>). In our study, we found that the induction of TNF-&#x3b1; promotes necroptosis via downstream TNFR and RIP molecules (<xref ref-type="sec" rid="s10">Supplementary Figure S4</xref>). In addition, activation of FASL and TLR was also observed during necroptosis (<xref ref-type="sec" rid="s10">Supplementary Figure S4</xref>). Accordingly, the identification of molecular determinants of necroptosis may have major therapeutic implications in various diseases. Our analysis also predicted that TSPOAP1 and TSPO strongly regulate sirtuin signalling (<xref ref-type="sec" rid="s10">Supplementary Figures S5, S6</xref>), which may contribute to sirtuins mediated control and regulation of metabolism, oxidative stress, and DNA damage in inflammation and cancer (<xref ref-type="bibr" rid="B22">Houtkooper et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B12">Edatt et&#x20;al., 2020</xref>). Mitochondrial dysfunctionality is known to play dynamic roles in oxidative stress, apoptosis, metabolism, and immune responses (<xref ref-type="bibr" rid="B41">Nicolson 2014</xref>), was also found to be associated with TSPOAP1 and TSPO. It arises due to dysfunction in their ATP production and electron transport machinery leading to decreased ATP synthesis and increased reactive oxygen species, which ultimately results in metabolic syndrome and oxidative damage to tissues (<xref ref-type="bibr" rid="B41">Nicolson 2014</xref>). Our pathway analysis shows that TSPOAP1 and TSPO may regulate several key genes of mitochondrial complexes (<xref ref-type="sec" rid="s10">Supplementary Figure S7</xref>), which play indispensable roles in mitochondrial dysfunction. Furthermore, the regulation of inflammasomes was identified to be linked with TSPOAP1 and TSPO (<xref ref-type="sec" rid="s10">Supplementary Figure S8</xref>). Inflammasomes are the multiprotein complex of the innate immune system (NLRP3, NLRC4, AIM2, and caspase-11), which initiate an inflammatory response against foreign bodies and infections (<xref ref-type="bibr" rid="B19">Guo et&#x20;al., 2015</xref>) (<xref ref-type="sec" rid="s10">Supplementary Figure S8</xref>). Combining these pieces of information from the major signalling pathways of TSPOAP1 and TSPO, we can state that both proteins seem majorly involved in inflammation cascades and orchestrate a pivotal role in inflammation, oxidative stress, aging, cancer, and metabolic syndrome.</p>
</sec>
<sec id="s4-2">
<title>IPA Reveals Interaction Molecules of TSPOAP1 and TSPO</title>
<p>After predicting canonical pathways, we analyzed those pathways to discover the common as well as exclusive interacting molecules of TSPOAP1 and TSPO. Statistical analyses of interacting proteins distributed in the canonical pathways of TSPOAP1 and TSPO revealed TNFR1, VCAM1, CREB1, NLRP3, and DNA-PK as the common interacting partners of both proteins (<xref ref-type="fig" rid="F2">Figures 2B,C</xref>). TSPOAP1 and TSPO mediate the inflammatory feedback through TNFR1 and downstream NF-&#x3ba;B, a transcription factor that promotes inflammation and carcinogenesis (<xref ref-type="bibr" rid="B47">Suthar and Sharma 2016</xref>). TSPOAP1 and TSPO also alter the activity of VCAM1, a transmembrane protein which facilitates the adhesion of leukocytes to endothelial cells (<xref ref-type="bibr" rid="B32">Kong et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B17">GeneCards, 2020</xref>). Furthermore, TSPOAP1 and TSPO play a central role in inflammation, apoptosis, and immune response by modulating the response of NLRP3 inflammasome. NLRP3 interacts with apoptosis-associated proteins, like ASC, and is induced by TLR ligands, such as lipopolysaccharide via NF-&#x3ba;B signalling; (<xref ref-type="bibr" rid="B7">Cocco et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B17">GeneCards, 2020</xref>). In addition, TSPOAP1 and TSPO mediate the activity of CREB1, a transcription factor, which promotes cell proliferation and differentiation via association with cAMP response element modulatory protein (Crem) and activating transcription factor 1 (Atf1) (<xref ref-type="bibr" rid="B2">Antony et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B13">Friedrich et&#x20;al., 2020</xref>). DNA-PK is a serine/threonine protein kinase, which acts as a molecular sensor against DNA damage and repairs it (<xref ref-type="bibr" rid="B39">Medov&#xe1; et&#x20;al., 2020</xref>). Abnormal expression and deregulation of DNA-PK lead to inflammatory disorders and cancer (<xref ref-type="bibr" rid="B39">Medov&#xe1; et&#x20;al., 2020</xref>). TSPOAP1 and TSPOP alter the response of DNA-PK against DNA damage. Taken together, the interaction of both TSPOAP1 and TSPO with these proteins supports the overlapping functions of TSPOAP1 and TSPO, including shared roles in inflammation, oxidative stress, metabolic syndrome, and cancer.</p>
<p>Besides the identification of common interaction partners of TSPOAP1 and TSPO, we also identified proteins that exclusively or favorably interact with either TSPOAP1 or TSPO, which could enable us in making the distinction between their functions. Our findings revealed that the percent distribution of TCR and mPTP were significantly higher in TSPOAP1 canonical pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>) than TSPO pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>). TCR is a protein that identifies foreign antigens on major histocompatibility complex (MHC) and activates T&#x20;cells through signal transduction mechanism (<xref ref-type="bibr" rid="B23">Hwang et&#x20;al., 2020</xref>); which may explain the key role of TSPOAP1 in the immune response. In addition, our analysis found mPTP significantly expressed in the TSPOAP1 pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>) compared to TSPO pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>), which was surprising considering the well-established association between the TSPO and mPTP (<xref ref-type="bibr" rid="B54">Veenman et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B11">Dimitrova-Shumkovska et&#x20;al., 2020</xref>). The mPTP is an event that occurs in response to injury and inflammation (<xref ref-type="bibr" rid="B36">Lemasters et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B33">Kwong and Molkentin 2015</xref>). The formation of mPTP induces mitochondrial cell death (<xref ref-type="bibr" rid="B33">Kwong and Molkentin 2015</xref>). The molecular structure of mPTP still remains a puzzle and far from settled (<xref ref-type="bibr" rid="B33">Kwong and Molkentin 2015</xref>). Historically, various studies suggested that mPTP is consisting of VDAC, ANT, and CypD (<xref ref-type="bibr" rid="B33">Kwong and Molkentin 2015</xref>). TSPO was also speculated to be a part of the mPTP core (<xref ref-type="bibr" rid="B38">McEnery et&#x20;al., 1992</xref>). However, recent genetic studies of each mPTP constitute have provided contrasting results. Studies have shown that VDAC<sup>&#x2212;/&#x2212;</sup> mitochondria are still able to form mPTP (<xref ref-type="bibr" rid="B3">Baines et&#x20;al., 2007</xref>) while genetic ablation of ANT also does not stop mitochondria from forming the mPTP (<xref ref-type="bibr" rid="B31">Kokoszka et&#x20;al., 2004</xref>). The deletion of TSPO in the mouse model still leads to mPTP formation (<xref ref-type="bibr" rid="B46">&#x160;ileikyt&#x117; et&#x20;al., 2014</xref>). Henceforth, the proteins which exactly comprise an mPTP structure remain an area of investigation. Our results revealed that it is TSPOAP1 instead of TSPO that predominantly interacts with mPTP; opens a new research paradigm on TSPOAP1&#x2019;s direct or indirect connection in the mPTP formation. We believe that further investigations on the role of TSPOAP1 in mPTP formation will immensely contribute to solving the conundrum of mPTP structure. At the same time, these studies will unmask the physiological and pathological role of TSPOAP1.</p>
<p>In the case of TSPO&#x2019;s exclusive interacting partners, we observed a high to the relatively high population of MAP3K10 and FCER1G in the canonical pathways compared to TSPOAP1 signalling cascades (<xref ref-type="fig" rid="F2">Figures 2B,C</xref>). MAP3K10 is stimulated in response to reactive oxygen species and inflammatory conditions; plays a critical role in the inflammation of brain tissues via the downstream JNK signalling pathway (<xref ref-type="bibr" rid="B52">Upadhyay et&#x20;al., 2019</xref>). FCER1G is a component of high-affinity immunoglobulin E, mediates allergic inflammatory signalling through downstream MAPK, phosphatidylinositol, and NF-&#x3ba;B signalling cascade (<xref ref-type="bibr" rid="B8">Cusabio 2021</xref>; <xref ref-type="bibr" rid="B50">UniProt 2021</xref>). Thus, the high population of MAP3K10 and FCER1G proteins in TSPO signalling suggests that TSPO mediates inflammatory response perhaps more extensively than TSPOAP1.</p>
</sec>
<sec id="s4-3">
<title>IPA Predicts Proteins Facilitating Communication Between TSPOAP1 and TSPO</title>
<p>To discover the molecules facilitating communication between TSPOAP1 and TSPO, we overlapped TSPOAP1 and TSPO signalling pathways (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref> and <xref ref-type="sec" rid="s10">Supplementary Figures S4&#x2013;S8</xref>) and their genes (<xref ref-type="sec" rid="s10">Supplementary Tables S1&#x2013;S3</xref>). Upon overlapping of pathways, VDAC1/2/3 emerged as the major communication bridge between TSPOAP1 and TSPO (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>), suggesting that two proteins interact with each other via chemical messengers facilitated by VDAC. VDAC1/2/3 or porin ion channels transport cargos between mitochondria and cytosol (<xref ref-type="bibr" rid="B49">Tsujimoto and Shimizu 2002</xref>; <xref ref-type="bibr" rid="B21">Hiller et&#x20;al., 2010</xref>), alter mPTP activity, and play a dynamic role in apoptosis (<xref ref-type="bibr" rid="B49">Tsujimoto and Shimizu 2002</xref>; <xref ref-type="bibr" rid="B35">Lemasters and Holmuhamedov 2006</xref>), suggesting that TSPOAP1 and TSPO may influence or modulate these functions.</p>
</sec>
<sec id="s4-4">
<title>IPA Predicts Diseases and Functions Linked to TSPOAP1 and TSPO</title>
<p>Finally, this study identified diseases and functions associated with TSPOAP1 and TSPO. Based on the heat map analysis of diseases and functions, TSPOAP1 can be explored as a potential drug target for phosphatidylglycerol-regulated functions, Alzheimer&#x27;s disease, progressive neurological disorder, adhesion of acute myeloid leukemia blast cells, and adhesion of human coronary artery endothelial cells (HCAEC) (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref> and <xref ref-type="sec" rid="s10">Supplementary Figures S9&#x2013;S10</xref>). Phosphatidylglycerol is a lipid that forms cardiolipin, a component of the inner mitochondrial membrane (<xref ref-type="bibr" rid="B44">Pizzuto and Pelegrin 2020</xref>). Cardiolipin maintains the electron transport chain and the activity of complex I, III, and IV and ATP synthase (<xref ref-type="bibr" rid="B44">Pizzuto and Pelegrin 2020</xref>). TSPOAP1 deregulates phosphatidylglycerol and thereby impairs the activity of cardiolipin in the brain, which leads to progressive neurological disorders and cancer. TSPOAP1 through adhesion of acute myeloid leukemia cells promotes resistance to chemotherapy, including cytarabine (<xref ref-type="bibr" rid="B4">Becker 2012</xref>). Therefore, TSPOAP1 can be explored as a potential drug target for drug-resistant acute myeloid leukemia. Based on its role in the adhesion of human coronary artery endothelial cells, TSPOAP1 may be a critical factor in various diseases, like atherosclerosis, and the development of TSPOAP1 ligands is a potential strategy for the treatment of coronary artery disease. Likewise, TSPO was predicted to be involved in neuroinflammatory, inflammatory, psychiatric, and metabolic diseases as well as cancer (<xref ref-type="sec" rid="s10">Supplementary Figures S11, S12</xref>). The involvement of TSPO in these diseases was expected because TSPO generates reactive oxygen species that form mPTP - the enigmatic gatekeeper of apoptosis and necroptosis, decreases ATP synthesis, and eventually results in cell death (<xref ref-type="bibr" rid="B53">Veenman et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B30">Kinnally et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B54">Veenman et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B58">Zeineh et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B11">Dimitrova-Shumkovska et&#x20;al., 2020</xref>). Besides our predictions of TSPO functions, a recent study by Yasin et&#x20;al. reported that TSPO regulates nuclear gene expression mainly through the mitochondria-to-nucleus signalling pathway (<xref ref-type="bibr" rid="B56">Yasin et&#x20;al., 2017</xref>). Our analysis reporting the roles of TSPO in various disease states contributes to the existing knowledge of the effect of TSPO on gene expression.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>This study identifies several canonical signalling pathways and proteins that interact with TSPOAP1 and TSPO, and also reveals the differences in the roles and functions of TSPOAP1 and TSPO. In addition, our data projects the potential roles of TSPOAP1 and TSPO in various diseases. These results provide guidance for experimental analyses of the mechanisms of action and functions of TSPOAP1, which are relatively unclear, particularly in comparison with its counterpart TSPO. Further research on TSPOAP1 could pave a way for the design and development of ligands targeting TSPOAP1 for the treatment of inflammatory diseases and cancer. At the same time, the development of TSPOAP1 selective ligands and biological assay for screening these ligands will help in revealing the pharmacological and biological actions of TSPOAP1. Based on our findings, IPA offers identification of several novel leads to study the detailed mechanisms and functioning of TSPOAP1 in human diseases, however, since these analytical predictions are derived from a myriad of context dependent experimental results stored in the Ingenuity Knowledge Base, the IPA outcomes may not always be emulated in a specific experimental set-up.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Data Availability Statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s10">Supplementary Material</xref>.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>SS, MA, JL, and SL conceived the idea, performed the experiments, and wrote the article. JM and AJ wrote and reviewed the article.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>The research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B03033429), and by a grant from the Korea Health Technology R&#x26;D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry for Health and Welfare, Korea (HI14C1135).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2021.667947/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmolb.2021.667947/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alam</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases</article-title>. <source>Nucl. Med. Mol. Imaging</source> <volume>51</volume> (<issue>4</issue>), <fpage>283</fpage>&#x2013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1007/s13139-017-0475-8</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antony</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>McDougall</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Mantamadiotis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>A. D.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Creb1 Regulates Late Stage Mammalian Lung Development via Respiratory Epithelial and Mesenchymal-independent Mechanisms</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <fpage>25569</fpage>. <pub-id pub-id-type="doi">10.1038/srep25569</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baines</surname>
<given-names>C. P.</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Sheiko</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Craigen</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Molkentin</surname>
<given-names>J.&#x20;D.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Voltage-dependent Anion Channels Are Dispensable for Mitochondrial-dependent Cell Death</article-title>. <source>Nat. Cel Biol.</source> <volume>9</volume> (<issue>5</issue>), <fpage>550</fpage>&#x2013;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1038/ncb1575</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>P. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment</article-title>. <source>Scientific World J.</source> <volume>2012</volume>, <fpage>1</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1100/2012/856467</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasi</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Influence of Benzodiazepines on Body Weight and Food Intake in Obese and Lean Zucker Rats</article-title>. <source>Prog. Neuro-Psychopharmacology Biol. Psychiatry</source> <volume>24</volume> (<issue>4</issue>), <fpage>561</fpage>&#x2013;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1016/s0278-5846(00)00093-2</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braestrup</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Squires</surname>
<given-names>R. F.</given-names>
</name>
</person-group> (<year>1977</year>). <article-title>Specific Benzodiazepine Receptors in Rat Brain Characterized by High-Affinity (3H)diazepam Binding</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>74</volume> (<issue>9</issue>), <fpage>3805</fpage>&#x2013;<lpage>3809</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.74.9.3805</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cocco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Garella</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Di Stilo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Borretto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stevanato</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Giorgis</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Electrophilic Warhead-Based Design of Compounds Preventing NLRP3&#x20;Inflammasome-dependent Pyroptosis</article-title>. <source>J.&#x20;Med. Chem.</source> <volume>57</volume> (<issue>24</issue>), <fpage>10366</fpage>&#x2013;<lpage>10382</lpage>. <pub-id pub-id-type="doi">10.1021/jm501072b</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="web">
<collab>Cusabio</collab> (<year>2021</year>). <article-title>Fc Epsilon RI Signalling Pathway</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.cusabio.cn/pathway/Fc-epsilon-RI-signalling-pathway.html">http://www.cusabio.cn/pathway/Fc-epsilon-RI-signalling-pathway.html</ext-link>
</comment> (<comment>Accessed April 15, 2021</comment>). </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Decaudin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Castedo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nemati</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Beurdeley-Thomas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Pinieux</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2002</year>). <article-title>Peripheral Benzodiazepine Receptor Ligands Reverse Apoptosis Resistance of Cancer Cells <italic>In Vitro</italic> and <italic>In Vivo</italic>
</article-title>. <source>Cancer Res.</source> <volume>62</volume> (<issue>5</issue>), <fpage>1388</fpage>&#x2013;<lpage>1393</lpage>. </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delavoie</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hardwick</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Robert</surname>
<given-names>J.-C.</given-names>
</name>
<name>
<surname>Giatzakis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>P&#xe9;ranzi</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>
<italic>In Vivo</italic> and <italic>In Vitro</italic> Peripheral-type Benzodiazepine Receptor Polymerization: Functional Significance in Drug Ligand and Cholesterol Binding</article-title>. <source>Biochemistry</source> <volume>42</volume> (<issue>15</issue>), <fpage>4506</fpage>&#x2013;<lpage>4519</lpage>. <pub-id pub-id-type="doi">10.1021/bi0267487</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitrova-Shumkovska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Krstanoski</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Veenman</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update</article-title>. <source>Cells</source> <volume>9</volume> (<issue>4</issue>), <fpage>870</fpage>. <pub-id pub-id-type="doi">10.3390/cells9040870</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Edatt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Poyyakkara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Raji</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Ramachandran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Shankar</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V. B. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Role of Sirtuins in Tumor Angiogenesis</article-title>. <source>Front. Oncol.</source> <volume>9</volume>, <fpage>1516</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.01516</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedrich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heimer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Stoehr</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Steven</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wach</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taubert</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>CREB1 Is Affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and Correlates with Adverse Clinicopathological Features in Renal Cell Carcinoma</article-title>. <source>Sci. Rep.</source> <volume>10</volume> (<issue>1</issue>), <fpage>6499</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-63403-y</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gali&#xe8;gue</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jbilo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Combes</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bribes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carayon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Le Fur</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>). <article-title>Cloning and Characterization of PRAX-1</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>274</volume> (<issue>5</issue>), <fpage>2938</fpage>&#x2013;<lpage>2952</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.5.2938</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Necroptosis: a Specialized Pathway of Programmed Necrosis</article-title>. <source>Cell</source> <volume>135</volume> (<issue>7</issue>), <fpage>1161</fpage>&#x2013;<lpage>1163</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.12.004</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garrido</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Galluzzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Brunet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Puig</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Didelot</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Mechanisms of Cytochrome C Release from Mitochondria</article-title>. <source>Cell Death Differ</source> <volume>13</volume> (<issue>9</issue>), <fpage>1423</fpage>&#x2013;<lpage>1433</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4401950</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="web">
<collab>GeneCards</collab> (<year>2020</year>). <article-title>GeneCards&#xae;: The Human Gene Database</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.genecards.org">https://www.genecards.org</ext-link>
</comment> (<comment>Accessed October 07, 2020</comment>). </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giatti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pesaresi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cavaletti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carozzi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Neuroprotective Effects of a Ligand of Translocator protein-18kDa (Ro5-4864) in Experimental Diabetic Neuropathy</article-title>. <source>Neuroscience</source> <volume>164</volume> (<issue>2</issue>), <fpage>520</fpage>&#x2013;<lpage>529</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.08.005</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Callaway</surname>
<given-names>J.&#x20;B.</given-names>
</name>
<name>
<surname>Ting</surname>
<given-names>J.&#x20;P.-Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Inflammasomes: Mechanism of Action, Role in Disease, and Therapeutics</article-title>. <source>Nat. Med.</source> <volume>21</volume> (<issue>7</issue>), <fpage>677</fpage>&#x2013;<lpage>687</lpage>. <pub-id pub-id-type="doi">10.1038/nm.3893</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heckmann</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Tummers</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Crashing the Computer: Apoptosis vs. Necroptosis in Neuroinflammation</article-title>. <source>Cel Death Differ</source> <volume>26</volume> (<issue>1</issue>), <fpage>41</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-018-0195-3</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiller</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abramson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mannella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zeth</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The 3D Structures of VDAC Represent a Native Conformation</article-title>. <source>Trends Biochem. Sci.</source> <volume>35</volume> (<issue>9</issue>), <fpage>514</fpage>&#x2013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2010.03.005</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houtkooper</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Pirinen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Sirtuins as Regulators of Metabolism and Healthspan</article-title>. <source>Nat. Rev. Mol. Cel. Biol.</source> <volume>13</volume> (<issue>4</issue>), <fpage>225</fpage>&#x2013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3293</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>J.-R.</given-names>
</name>
<name>
<surname>Byeon</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.-G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Recent Insights of T&#x20;Cell Receptor-Mediated Signaling Pathways for T&#x20;Cell Activation and Development</article-title>. <source>Exp. Mol. Med.</source> <volume>52</volume> (<issue>5</issue>), <fpage>750</fpage>&#x2013;<lpage>761</lpage>. <pub-id pub-id-type="doi">10.1038/s12276-020-0435-8</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iacobazzi</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Lopalco</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cutrignelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laquintana</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lopedota</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Bridging Pharmaceutical Chemistry with Drug and Nanoparticle Targeting to Investigate the Role of the 18-kDa Translocator Protein TSPO</article-title>. <source>ChemMedChem</source> <volume>12</volume> (<issue>16</issue>), <fpage>1261</fpage>&#x2013;<lpage>1274</lpage>. <pub-id pub-id-type="doi">10.1002/cmdc.201700322</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ilkan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Akar</surname>
<given-names>F. G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The Mitochondrial Translocator Protein and the Emerging Link between Oxidative Stress and Arrhythmias in the Diabetic Heart</article-title>. <source>Front. Physiol.</source> <volume>9</volume>, <fpage>1518</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2018.01518</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="web">
<collab>IPA</collab> (<year>2020a</year>). <article-title>Ingenuity Pathway Analysis (IPA), Qiagen</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-ipa">https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-ipa</ext-link>
</comment> (<comment>Accessed August 29, 2020</comment>). </citation>
</ref>
<ref id="B27">
<citation citation-type="web">
<collab>IPA</collab> (<year>2020b</year>). <article-title>Ingenuity Pathway Analysis (IPA), Qiagen</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://qiagen.force.com/KnowledgeBase/articles">http://qiagen.force.com/KnowledgeBase/articles</ext-link>
</comment> (<comment>Accessed September 11, 2020</comment>). </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jun</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Beecham</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>D. A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Transethnic Genome-wide Scan Identifies Novel Alzheimer&#x27;s Disease Loci</article-title>. <source>Alzheimers Dement</source> <volume>13</volume> (<issue>7</issue>), <fpage>727</fpage>&#x2013;<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2016.12.012</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jeon</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>S.-J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Tanycytic TSPO Inhibition Induces Lipophagy to Regulate Lipid Metabolism and Improve Energy Balance</article-title>. <source>Autophagy</source> <volume>16</volume> (<issue>7</issue>), <fpage>1200</fpage>&#x2013;<lpage>1220</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2019.1659616</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kinnally</surname>
<given-names>K. W.</given-names>
</name>
<name>
<surname>Peixoto</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Dejean</surname>
<given-names>L. M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Is mPTP the Gatekeeper for Necrosis, Apoptosis, or Both?</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Cel Res.</source> <volume>1813</volume> (<issue>4</issue>), <fpage>616</fpage>&#x2013;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2010.09.013</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kokoszka</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Waymire</surname>
<given-names>K. G.</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Sligh</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D. P.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>The ADP/ATP Translocator Is Not Essential for the Mitochondrial Permeability Transition Pore</article-title>. <source>Nature</source> <volume>427</volume> (<issue>6973</issue>), <fpage>461</fpage>&#x2013;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1038/nature02229</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>D-H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>19</volume> (<issue>4</issue>), <fpage>1057</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19041057</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwong</surname>
<given-names>J.&#x20;Q.</given-names>
</name>
<name>
<surname>Molkentin</surname>
<given-names>J.&#x20;D.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Physiological and Pathological Roles of the Mitochondrial Permeability Transition Pore in the Heart</article-title>. <source>Cel Metab.</source> <volume>21</volume> (<issue>2</issue>), <fpage>206</fpage>&#x2013;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.001</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nam</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.-W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Translocator Protein (TSPO): the New story of the Old Protein in Neuroinflammation</article-title>. <source>BMB Rep.</source> <volume>53</volume> (<issue>1</issue>), <fpage>20</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.5483/BMBRep.2020.53.1.273</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemasters</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Holmuhamedov</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Voltage-dependent Anion Channel (VDAC) as Mitochondrial Governator-Thinking outside the Box</article-title>. <source>Biochim. Biophys. Acta (Bba) - Mol. Basis Dis.</source> <volume>1762</volume> (<issue>2</issue>), <fpage>181</fpage>&#x2013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2005.10.006</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lemasters</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Theruvath</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Nieminen</surname>
<given-names>A.-L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Mitochondrial Calcium and the Permeability Transition in Cell Death</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1787</volume> (<issue>11</issue>), <fpage>1395</fpage>&#x2013;<lpage>1401</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2009.06.009</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hardwick</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Culty</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Peripheral-type Benzodiazepine Receptor Overexpression and Knockdown in Human Breast Cancer Cells Indicate its Prominent Role in Tumor Cell Proliferation</article-title>. <source>Biochem. Pharmacol.</source> <volume>73</volume> (<issue>4</issue>), <fpage>491</fpage>&#x2013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2006.10.025</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McEnery</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Snowman</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Trifiletti</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Snyder</surname>
<given-names>S. H.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Isolation of the Mitochondrial Benzodiazepine Receptor: Association with the Voltage-dependent Anion Channel and the Adenine Nucleotide Carrier</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>89</volume>, <fpage>3170</fpage>&#x2013;<lpage>3174</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.89.8.3170</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Medov&#xe1;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Medo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hovhannisyan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz-Maldonado</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Aebersold</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>DNA-PK in Human Malignant Disorders: Mechanisms and Implications for Pharmacological Interventions</article-title>. <source>Pharmacol. Ther.</source> <volume>215</volume>, <fpage>107617</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107617</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="web">
<collab>NCBI</collab> (<year>2020</year>). <article-title>National Center for Biotechnology (NCBI)</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gene">https://www.ncbi.nlm.nih.gov/gene</ext-link>
</comment> (<comment>Accessed August 26, 2020</comment>). </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicolson</surname>
<given-names>G. L.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Mitochondrial Dysfunction and Chronic Disease: Treatment with Natural Supplements</article-title>. <source>Altern Ther Health Med.</source> <volume>13</volume> (<issue>4</issue>), <fpage>35</fpage>&#x2013;<lpage>43</lpage>. </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadopoulos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lecanu</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Translocator Protein (18 kDa) TSPO: an Emerging Therapeutic Target in Neurotrauma</article-title>. <source>Exp. Neurol.</source> <volume>219</volume> (<issue>1</issue>), <fpage>53</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2009.04.016</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadopoulos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Culty</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Is There a Mitochondrial Signalling Complex Facilitating Cholesterol Import?</article-title> <source>Mol. Cel. Endocrinol.</source> <volume>265&#x2013;266</volume>, <fpage>59</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2006.12.004</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pizzuto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pelegrin</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Cardiolipin in Immune Signalling and Cell Death</article-title>. <source>Trends Cel Biol.</source> <volume>30</volume> (<issue>11</issue>), <fpage>892</fpage>&#x2013;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2020.09.004</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rupprecht</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rammes</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Baghai</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Akula</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Translocator Protein (18 kDa) (TSPO) as a Therapeutic Target for Neurological and Psychiatric Disorders</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>9</volume> (<issue>12</issue>), <fpage>971</fpage>&#x2013;<lpage>988</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3295</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#x160;ileikyt&#x117;</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blachly-Dyson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sewell</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carpi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Menab&#xf2;</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Di Lisa</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Regulation of the Mitochondrial Permeability Transition Pore by the Outer Membrane Does Not Involve the Peripheral Benzodiazepine Receptor (Translocator Protein of 18&#x20;kDa (TSPO))</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>289</volume> (<issue>20</issue>), <fpage>13769</fpage>&#x2013;<lpage>13781</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.549634</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suthar</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Recent Developments in Chimeric NSAIDs as Anticancer Agents: Teaching an Old Dog a New Trick</article-title>. <source>Mini Rev. Med. Chem.</source> <volume>16</volume> (<issue>15</issue>), <fpage>1201</fpage>&#x2013;<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.2174/1389557516666160428111419</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="web">
<collab>Swiss-Model</collab> (<year>2020</year>). <article-title>Swiss-model</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://swissmodel.expasy.org/interactive">https://swissmodel.expasy.org/interactive</ext-link>
</comment> (<comment>Accessed September 5, 2020</comment>). </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsujimoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>The Voltage-dependent Anion Channel: an Essential Player in Apoptosis</article-title>. <source>Biochimie</source> <volume>84</volume> (<issue>2-3</issue>), <fpage>187</fpage>&#x2013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/s0300-9084(02)01370-6</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="web">
<collab>UniProt</collab> (<year>2021</year>). <article-title>High Affinity Immunoglobulin Epsilon Receptor Subunit Gamma</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/uniprot/P30273">https://www.uniprot.org/uniprot/P30273</ext-link>
</comment> (<comment>Accessed April 15, 2021</comment>). </citation>
</ref>
<ref id="B51">
<citation citation-type="web">
<collab>UniProt</collab> (<year>2020</year>). <article-title>Peripheral-type Benzodiazepine Receptor-Associated Protein 1</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="https://ebi14.uniprot.org/uniprot/O95153">https://ebi14.uniprot.org/uniprot/O95153</ext-link>
</comment> (<comment>Accessed September 5, 2020</comment>). </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upadhyay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hosseinibarkooie</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaczmarek</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torres-Benito</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mendoza-Ferreira</surname>
<given-names>L. N.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Neurocalcin delta Knockout Impairs Adult Neurogenesis whereas Half Reduction Is Not Pathological</article-title>. <source>Front. Mol. Neurosci.</source> <volume>12</volume>, <fpage>19</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2019.00019</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veenman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alten</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Linnemannst&#xf6;ns</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shandalov</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zeno</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lakomek</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Potential Involvement of F0F1-ATP(synth)ase and Reactive Oxygen Species in Apoptosis Induction by the Antineoplastic Agent Erucylphosphohomocholine in Glioblastoma Cell Lines A Mechanism for Induction of Apoptosis via the 18&#x20;kDa Mitochondrial Translocator Protein</article-title>. <source>Apoptosis</source> <volume>15</volume> (<issue>7</issue>), <fpage>753</fpage>&#x2013;<lpage>768</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-010-0460-5</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veenman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shandalov</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gavish</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>VDAC Activation by the 18&#x20;kDa Translocator Protein (TSPO), Implications for Apoptosis</article-title>. <source>J.&#x20;Bioenerg. Biomembr.</source> <volume>40</volume> (<issue>3</issue>), <fpage>199</fpage>&#x2013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1007/s10863-008-9142-1</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witoelar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rongve</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Almdahl</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>Ulstein</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Engvig</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>L. R.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Meta-analysis of Alzheimer&#x2019;s Disease on 9751 Samples from Norway and IGAP Study Identifies Four Risk Loci</article-title>. <source>Sci. Rep.</source> <volume>8</volume> (<issue>1</issue>), <fpage>18088</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-36429-6</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Veenman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Azrad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vainshtein</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Classical and Novel TSPO Ligands for the Mitochondrial TSPO Can Modulate Nuclear Gene Expression: Implications for Mitochondrial Retrograde Signalling</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>18</volume> (<issue>4</issue>), <fpage>786</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18040786</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yim</surname>
<given-names>N. H.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Hypermethylation of the TSPOAP1-AS1 Promoter May Be Associated with Obesity in Overweight/obese Korean Subjects</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>21</volume> (<issue>9</issue>), <fpage>3307</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21093307</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeineh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nagler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gabay</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Weizman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gavish</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Effects of Cigarette Smoke on TSPO-Related Mitochondrial Processes</article-title>. <source>Cells</source> <volume>8</volume> (<issue>7</issue>), <fpage>694</fpage>. <pub-id pub-id-type="doi">10.3390/cells8070694</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>